News | 18 June 2026
Bayer seals $300 million Perfuse deal
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
Leading experts from AIIMS Kalyani, Syngene, Veeda Lifesciences, Lambda Therapeutic, DNDi, JSS Medical, KIHT, InoRx, ISCR and SIRO Clintech to discuss India’s readiness as preferred clinical research destination
Market grows 12.1%; volume contribution improves as 9 out of 10 key therapies post double-digit growth
The FDA nod marks a step forward in precision oncology, linking molecular diagnostics more tightly to therapy selection for advanced prostate cancer
New facility will open by October 2026 and house 500 process development specialists
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies
Exclusive licensing agreement combines Lonza’s dual-payload ADC technology with Antharis’ antibody engineering expertise
Samelisant will be the centerpiece of Suven’s scientific presence
Cervical cancer remains one of the leading causes of cancer deaths among women in India
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
Partnership will provide funding, incubation, mentorship, and industry exposure for ventures in healthcare, pharmaceuticals, biotechnology, medical technology, and agriculture
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
The film tells the story of a 70-year-old woman from Kota, Rajasthan, whose persistent cough led to a diagnosis of advanced lung cancer
The collaboration aims to develop differentiated biologics that offer greater convenience and accessibility for patients
Developed by the Sudha Gopalakrishnan Brain Centre, the publicly accessible ANCHOR atlas maps over 200 brainstem structures at cellular resolution, offering new possibilities for neuroscience research and clinical applications
Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
First-in-class topical androgen receptor inhibitor marks Glenmark’s first New Chemical Entity (NCE) launch in Europe
Subscribe To Our Newsletter & Stay Updated
